# Myasthenia Gravis and Thymoma

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/myasthenia-gravis-and-thymoma/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the research related to myasthenia gravis, including its subgroups, clinical correlates, treatment strategies, and the role of autoantibodies. Additionally, it explores the classification and prognosis of thymic tumors, the efficacy of thymectomy, and the epidemiology of these conditions. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11271 |
| Works | 108 |

## Topic papers all

Showing 15 of 108.

- [Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies](https://scholariq.org/papers/auto-antibodies-to-the-receptor-tyrosine-kinase-musk-in-patients-with-myasthenia/)
- [International consensus guidance for management of myasthenia gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis/)
- [Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: International standards guideline statement](https://scholariq.org/papers/electrophysiologic-recurrent-laryngeal-nerve-monitoring-during-thyroid-and/)
- [Randomized Trial of Thymectomy in Myasthenia Gravis](https://scholariq.org/papers/randomized-trial-of-thymectomy-in-myasthenia-gravis/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [International Consensus Guidance for Management of Myasthenia Gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis-2/)
- [Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I](https://scholariq.org/papers/autoantibodies-against-il-17a-il-17f-and-il-22-in-patients-with-chronic/)
- [Selumetinib in Children with Inoperable Plexiform Neurofibromas](https://scholariq.org/papers/selumetinib-in-children-with-inoperable-plexiform-neurofibromas/)
- [Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised/)
- [Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist](https://scholariq.org/papers/long-term-treatment-of-acromegaly-with-pegvisomant-a-growth-hormone-receptor/)
- [The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes](https://scholariq.org/papers/the-2015-world-health-organization-classification-of-tumors-of-the-thymus/)
- [Superior Vena Cava Syndrome with Malignant Causes](https://scholariq.org/papers/superior-vena-cava-syndrome-with-malignant-causes/)
- [Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study](https://scholariq.org/papers/derivation-and-external-validation-of-the-plasmic-score-for-rapid-assessment-of/)
- [IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†](https://scholariq.org/papers/igg1-antibodies-to-acetylcholine-receptors-in-seronegative-myasthenia-gravis/)
- [Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study](https://scholariq.org/papers/pembrolizumab-in-patients-with-thymic-carcinoma-a-single-arm-single-centre-phase/)

## Topic primary papers

Showing 15 of 72.

- [Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies](https://scholariq.org/papers/auto-antibodies-to-the-receptor-tyrosine-kinase-musk-in-patients-with-myasthenia/)
- [International consensus guidance for management of myasthenia gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis/)
- [Randomized Trial of Thymectomy in Myasthenia Gravis](https://scholariq.org/papers/randomized-trial-of-thymectomy-in-myasthenia-gravis/)
- [Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study](https://scholariq.org/papers/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody/)
- [International Consensus Guidance for Management of Myasthenia Gravis](https://scholariq.org/papers/international-consensus-guidance-for-management-of-myasthenia-gravis-2/)
- [Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised/)
- [The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes](https://scholariq.org/papers/the-2015-world-health-organization-classification-of-tumors-of-the-thymus/)
- [IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†](https://scholariq.org/papers/igg1-antibodies-to-acetylcholine-receptors-in-seronegative-myasthenia-gravis/)
- [Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study](https://scholariq.org/papers/pembrolizumab-in-patients-with-thymic-carcinoma-a-single-arm-single-centre-phase/)
- [The Integrated Genomic Landscape of Thymic Epithelial Tumors](https://scholariq.org/papers/the-integrated-genomic-landscape-of-thymic-epithelial-tumors/)
- [Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial](https://scholariq.org/papers/pembrolizumab-for-patients-with-refractory-or-relapsed-thymic-epithelial-tumor/)
- [The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?](https://scholariq.org/papers/the-2021-who-classification-of-tumors-of-the-thymus-and-mediastinum-what-is-new/)
- [Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial](https://scholariq.org/papers/sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma/)
- [Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study](https://scholariq.org/papers/safety-and-efficacy-of-zilucoplan-in-patients-with-generalised-myasthenia-gravis/)
- [A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors](https://scholariq.org/papers/a-specific-missense-mutation-in-gtf2i-occurs-at-high-frequency-in-thymic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.